Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(0.91)
# 3,625
Out of 4,826 analysts
130
Total ratings
27.83%
Success rate
-29.65%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $28 → $20 | $2.59 | +673.69% | 9 | May 2, 2025 | |
| IMUX Immunic | Reiterates: Buy | $10 | $1.13 | +788.89% | 4 | May 1, 2025 | |
| UBX Unity Biotechnology | Reiterates: Buy | $4 | $1.07 | +273.83% | 8 | Apr 23, 2025 | |
| LENZ LENZ Therapeutics | Reiterates: Buy | $30 | $29.10 | +3.09% | 4 | Apr 16, 2025 | |
| ADVM Adverum Biotechnologies | Reiterates: Buy | $30 | $3.58 | +737.99% | 5 | Apr 16, 2025 | |
| ALDX Aldeyra Therapeutics | Reiterates: Buy | $10 | $2.70 | +270.37% | 12 | Apr 4, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $30 → $42 | $15.64 | +168.63% | 7 | Apr 2, 2025 | |
| SRZN Surrozen | Reiterates: Buy | $32 | $10.25 | +212.20% | 2 | Apr 2, 2025 | |
| FBLG FibroBiologics | Reiterates: Buy | $12 | $0.95 | +1,161.56% | 4 | Apr 1, 2025 | |
| IRD Opus Genetics | Reiterates: Buy | $8 | $0.95 | +746.56% | 3 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $1.91 | +4.71% | 6 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3 | $4.93 | -39.15% | 4 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $3.41 | -41.35% | 7 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $1.14 | +75.44% | 16 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $9 | $9.43 | -4.56% | 7 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $4.03 | +148.14% | 4 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $0.10 | +1,824.93% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $11.35 | +164.32% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $3.57 | +908.40% | 18 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $220.90 | -87.32% | 1 | Aug 22, 2023 |
Phathom Pharmaceuticals
May 2, 2025
Maintains: Buy
Price Target: $28 → $20
Current: $2.59
Upside: +673.69%
Immunic
May 1, 2025
Reiterates: Buy
Price Target: $10
Current: $1.13
Upside: +788.89%
Unity Biotechnology
Apr 23, 2025
Reiterates: Buy
Price Target: $4
Current: $1.07
Upside: +273.83%
LENZ Therapeutics
Apr 16, 2025
Reiterates: Buy
Price Target: $30
Current: $29.10
Upside: +3.09%
Adverum Biotechnologies
Apr 16, 2025
Reiterates: Buy
Price Target: $30
Current: $3.58
Upside: +737.99%
Aldeyra Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $10
Current: $2.70
Upside: +270.37%
Mineralys Therapeutics
Apr 2, 2025
Maintains: Buy
Price Target: $30 → $42
Current: $15.64
Upside: +168.63%
Surrozen
Apr 2, 2025
Reiterates: Buy
Price Target: $32
Current: $10.25
Upside: +212.20%
FibroBiologics
Apr 1, 2025
Reiterates: Buy
Price Target: $12
Current: $0.95
Upside: +1,161.56%
Opus Genetics
Apr 1, 2025
Reiterates: Buy
Price Target: $8
Current: $0.95
Upside: +746.56%
Mar 31, 2025
Reiterates: Neutral
Price Target: $2
Current: $1.91
Upside: +4.71%
Mar 31, 2025
Reiterates: Neutral
Price Target: $3
Current: $4.93
Upside: -39.15%
Mar 25, 2025
Downgrades: Neutral
Price Target: $12 → $2
Current: $3.41
Upside: -41.35%
Mar 21, 2025
Reiterates: Neutral
Price Target: $2
Current: $1.14
Upside: +75.44%
Mar 21, 2025
Downgrades: Neutral
Price Target: $18 → $9
Current: $9.43
Upside: -4.56%
Mar 19, 2025
Maintains: Buy
Price Target: $7 → $10
Current: $4.03
Upside: +148.14%
Mar 14, 2025
Reiterates: Neutral
Price Target: $2
Current: $0.10
Upside: +1,824.93%
Mar 12, 2025
Reiterates: Buy
Price Target: $30
Current: $11.35
Upside: +164.32%
Mar 3, 2025
Reiterates: Buy
Price Target: $36
Current: $3.57
Upside: +908.40%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $220.90
Upside: -87.32%